Evidence map›Paper›PMID 40589911›Full record

ArticleERJ open research2025

Treatment choice for adult patients with moderate-to-severe asthma: the TAILOR study.

Daniel Jeannetot, Maria de Ridder, Mees Mosseveld, Lars Pedersen, Francesco Lapi, Ettore Marconi, Eng Hooi Tan, Antonella Delmestri, Daniel Prieto-Alhambra, Marielle Van Der Deijl and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Daniel JeannetotDepartment of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID https://orcid.org/0000-0001-8797-0883
Maria de RidderDepartment of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.
Mees MosseveldDepartment of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID https://orcid.org/0000-0001-9301-8565
Lars PedersenDepartment of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.
Francesco LapiSIMG - Italian College of General Practitioners and Primary Care, Florence, Italy.
Ettore MarconiSIMG - Italian College of General Practitioners and Primary Care, Florence, Italy.
Eng Hooi TanCentre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.ORCID https://orcid.org/0000-0003-4470-2736
Antonella DelmestriCentre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.ORCID https://orcid.org/0000-0003-0388-3403
Daniel Prieto-AlhambraDepartment of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.
Marielle Van Der DeijlGlobal Medical Affairs, Chiesi Farmaceutici, S.p.A, Parma, Italy.
Guy BrusselleDepartment of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.ORCID https://orcid.org/0000-0001-7021-8505
Katia VerhammeDepartment of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID https://orcid.org/0000-0001-8162-4904

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In patients with uncontrolled asthma treated with medium dose inhaled corticosteroid/long-acting β Methods: A retrospective cohort study using three primary care databases (IPCI, HSD, CPRD GOLD) and one prescription database (Aarhus) included asthma patients with step-up after ≥3 months use of medium-dose ICS/LABA, from January 2010 to April 2020. Characteristics of patients were described, and determinants of choice for medium-dose ICS/LABA+LAMA or high dose ICS/LABA were investigated. Results: 492 639 adults with asthma and ≥1 year of database history were identified and 25 558 were eligible for analysis. 6126 patients stepped-up to medium-dose ICS/LABA+LAMA and 18 947 patients stepped-up to high-dose ICS/LABA. Determinants for step-up to medium-dose ICS/LABA+LAMA were higher age and presence of COPD whereas history of atopy lowered this choice. Other covariates were differentially associated with specific treatment step-up depending on the databases. Conclusion: In uncontrolled asthma patients on medium-dose ICS/LABA, treatment step-up with add-on LAMA was more likely than step-up to high-dose ICS/LABA in older patients, current smokers, with a history of asthma exacerbations and concomitant diagnosis of COPD.

Identifiers

PMID40589911
PMCPMC12208605

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.